The interest in vitamin D has exploded during the last decade, illustrated by the number of new vitamin D related articles registered in PubMed which is between 50 and 100 every week. This is also reflected in the lay press with numerous articles promoting the beneficial effects of the Dlightful sun-shine hormone vitamin D. If read uncritically, vitamin D appears to be good for almost any condition thinkable and is today the hottest magic cure. But why has this happened?
First of all, vitamin D is nature's own product, an ancient hormone produced in the skin by sun exposure. It promotes the intestinal calcium absorption, has a well-known effect in preventing and curing rickets, and vitamin D's role in calcium metabolism and skeletal health is indisputable.
1 Secondly, the enzyme necessary for the final activation of vitamin D as well as the vitamin D receptor (VDR) have recently been identified in tissues throughout the body, and extra-skeletal effects of vitamin D were therefore to be expected. 2 Thus, when methods for measuring 25(OH)D (the most abundant vitamin D metabolite and the one used to evaluate a subject's vitamin D status) became widely available, numerous observational studies were published. And almost without exception, high serum 25(OH)D levels were associated with good health, while low levels were predictors of type II diabetes, cancer, cardiovascular disease (CVD), immunological diseases and even mortality. 3 In 4751 participants in the Tromsø study from Northern Norway, those in the lowest serum 25(OH)D quartile had over a follow-up period of 11 years a 32 % increased mortality risk as compared to those in the highest 25(OH)D quartile. 4 And similarly, in the 1739 subjects in the Framingham Offspring Study followed for 5.4 years, those with serum 25(OH)D levels < 10 ng/ml had a hazard ratio of 1.80 for a cardiovascular event as compared to those with levels > 15 ng/ml. u ubj bj jec e t's vitami mi in n n D D D st sta atu us us) ) ) be be bec ca came me me w w wi id de e ely a a ava a ailab bl ble e, n n num um mer er ro ou us s o ob obse erv rvat atio iona na nal l l st stud ud die ie es s w we wer re re pu publ bl b is is ishe he h d. d. A A And nd a a alm m mos ost t w wi with thou ou ut t ex ex exce ce cept pti io ion, n, n h h hig igh h h se se eru u um m 25 25 5(O (O (OH) H) H)D D D le leve ve vels ls w w wer ere e e as as sso soc ci cia at ated ed d w w wit ith h go o ood health, while e lo lo low w w le le leve ve vels ls ls w w er er ere e e pr r red ed edic ic cto t t rs rs rs o o of f f t t typ yp ype e e II II II d d dia ia iabe be ete te tes, s, s, c c can an ance ce c r, r, , c c car ar ardi di diov ov ovas as a cu cu cula la lar r r di di dise s ase To avoid this bias and to address the key question on causality, the traditional approach has been randomized clinical trials (RCTs), which however are time consuming and expensive. For hard endpoints like CVD or death the number of patients needed in such trials is usually from 5,000 to 10,000, and even for a "surrogate" endpoint like serum lipids the number needed is substantial.
Thus, if wanting to show a 5 % decrease in LDL cholesterol levels, which corresponds to the difference between subjects with serum 25(OH)D < 20 ng/ml and subjects with levels > 30 ng/ml reported in the present issue of Circulation by Ponda et al., 10 one would have to include at least 1200 subjects if wanting a power of 0.80 and a significance level of 0.05. A more realistic expectation would be a lowering of 2.5 % and then one would have to include close to 4000 subjects.
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To To a a avo vo void id t thi hi his s s bi bia a as a and nd d to o o ad a dr dr dres s ss s s th th the e e k ke ey y y qu qu ques esti ti tion on n o o on n ca ca c us us usal a alit t ty, y, y t t th he e e tr tr trad ad dit tio iona na nal l ap ap appr pr pro oa oach ch h h h has as b be e een andomized c cli li lini ni n ca ca cal l l tr tr ria ia ials l ( ( (RC RC RCTs Ts Ts), ), ) w w whi hich ch ch h h how ow owev ev ver er e a are re r t tim im ime e e co co cons ns nsum um umin in ing g g an an and d d ex expe pe pens ns nsiv iv ive. e e For hard Based on more than 4 million patient laboratory test results they were able to select a group of 108,711 subjects who had repeated serum 25(OH)D and lipid testing 4 to 26 weeks apart. In both men and women there was with increasing 25(OH)D strata a modest but highly significant decrease in total cholesterol, LDL cholesterol and triglycerides, and an increase in HDL cholesterol. This is basically confirmatory of what has been published by others as summarized in two recent reviews on vitamin D and lipids. 8, 9 More interesting, however, are the results from the "interventional" or longitudinal part of the study. Among the 108,711 subjects, 6,260 had serum 25(OH)D levels < 20 ng/ml that after 4
to 26 weeks had increased to between 30 and 100 ng/ml ("repletion" group), and 2,332 patients had 25(OH)D levels < 20 ng/ml at both measurements ("control" group). In the "repletion"
group there was an increase in serum 25(OH)D of 27.3 ng/ml, whereas the increase in the So, does this rule out a beneficial effect of vitamin D on the serum lipid profile and make o 26 weeks had increased to between 30 and 100 ng/ml ("repletion" group), and d 2 2,3 ,3 332 32 2 p p pat at atie ie ient nts had 25(OH)D levels < 20 ng/ml at both measurements ("control" group). In the "repletion" gr grou ou up p p th th ther er re e e w w was s an an an i increase in serum 25(OH)D of of of 2 2 27.3 ng/ml, whe he h reas as s th th the increase in the " "c con n ontrol" grou up p wa w was s o on only ly ly 0 0 0.9 .9 9 n n ng/ g/ml ml ml. 12 The only effect on the lipid profile that reached statistical significance was a small increase in LDL cholesterol of 3.23 mg/ml, whereas there was a non-significant increase in total cholesterol of 1.52 mg/dl, a reduction in HDL cholesterol of 0.14 mg/dl, and a reduction in triglycerides of 1.92 mg/dl.
However, most of the studies included were small, the doses of vitamin D given ranged from 300 IU to ~ 6000 IU per day, the duration ranged from 8 weeks to 3 years, none of them had high lipid levels as inclusion criteria, and at baseline the majority of the subjects were not vitamin D deficient. In spite of these short-comings, when this meta-analysis is considered together with the results reported by Ponda et al., 10 it appears highly unlikely that oral supplementation with vitamin D will have any clinically significant positive effect on the serum lipid levels, with the possible reservation that subjects with a combination of vitamin D deficiency and hyperlipidemia still need to be studied.
Then on the other hand, is it possible that the study by Ponda et al., 10 due to its design, masks significant and important negative effects of vitamin D? As the authors themselves point out, they have performed an observational study which is critically different from an RCT. The subjects were not randomized and to no surprise there were important differences between the "repletion" and "control" groups at baseline. The first serum LDL cholesterol and triglyceride eduction in HDL cholesterol of 0.14 mg/dl, and a reduction in triglycerides of 1 1. .9 .92 2 2 mg mg mg/d /d /dl. l. l However, most of the studies included were small, the doses of vitamin D given ranged from 300 f U U t t to o o ~ 60 60 6000 00 00 IU U pe pe per r day, the duration ranged fro o om m m 8 8 weeks to 3 ye ye years, s, n n no on one of them had high i i ipid d d levels as in incl c u us usio io ion cr cr crit it ite er eria ia ia, , an an nd d d at at t b b basel el lin n ne th h he e ma a ajo jo jori rit ty ty o of f t th he e e su subj bj b e ec cts ts w w wer ere e no no not t t vi vi v ta a ami mi min n n D D D de defi fi fici ci ien en e t. t. I I In n n sp spit ite e o of of t th he hese se s sho ho hort rt t-c -c -com om omin in ngs gs gs, , w wh when en en t th h his s s m m met et ta-a-a-a an anal al alys ys ysis is i i is s s co co on ns sid id der er e ed ed e t t tog og oget eth h her r r wi with th t the esults report rted ed ed b by y y Po Po P nd nd nda et et et a a al., , 10 10 10 i it t ap ap a pe pe pear ar ars s s hi hi high gh ghly ly ly u u unl n ik ik kel el ely y y th th that at at o ora a al l l su su supp pp pple le leme me ent nt ntat at a io io ion n n with levels differed significantly between the two groups. Also, the subjects in the "repletion" group were more likely to have a diagnosis of lipid disorder and/or hypertension than the "control" group, and accordingly, more likely to receive some sort of treatment or advice regarding lipids than the "controls". And most important, subjects with serum 25(OH)D levels below 20 ng/ml are probably advised (or should be) to take some sort or vitamin D supplementation. It is highly unlikely that the subjects who followed that advice (or who had the initiative to ask for the result of the 25(OH)D measurement, or who had a physician who took the responsibility to follow-up low serum 25(OH)D levels) are identical to the subjects who did not receive or follow advice on vitamin D substitution. An improvement in the serum lipid levels could therefore have been expected in the "repletion" group unrelated to an effect of the vitamin D substitution. However, that was not seen. One could therefore suspect that a negative effect of vitamin D on the serum lipids, as indicated in the vitamin D meta-analysis, 12 was masked in the present study.
Furthermore, as emphasised by the authors, no information on medication was available, which in this study was particularly important as statins by themselves may affect the serum 25(OH)D levels. 13 In spite of the above objections and shortcomings, the study by Ponda el al. 10 is of great importance as it underscores that cross-sectional results are not necessarily reproduced in prospective studies, and that cross-sectional data cannot and should never be taken as evidence Fu Furt t rthe h rmore, a as s em em mph ph phas asis is ised ed ed b b by y y th th he e e au au a th tho ors, no o o info form rmat at atio ion n n o on n m m me ed dic icat at tio on n wa wa was s av avai ai aila la labl bl b e, e, , w wh hi h c c ch n n t t thi hi his s s st stud ud dy y y wa was s s pa pa part rti ic cu ul ular arly y y i i mp mp mpor or ort ta tan nt nt a a as s s st st stat t tin in ins s by y y th he hems ms mse e elve ve ves s ma ma may y y a a affe fe ect ct t t the he e s ser er eru um um 2 2 25 5( 5(OH OH H)D )D D evels. selenium have all been promising but on proper testing turned out to be disappointing. 15 A similar approach as the one presented by Ponda et al. 10 could be used by others who have access to large databases with laboratory test results from more than one time point, and particularly if the data can be merged with data bases with clinical information and outcomes.
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